Malcolm Rowland

Q: What Schools Are Affiliated With Malcolm Rowland

Malcolm Rowland is affiliated with the following schools: University of Nottingham, University of Arizona, University of Manchester

Malcolm Rowland's AcademicInfluence.com Rankings

Malcolm Rowland

Medical

#1184

World Rank

#1498

Historical Rank

Pharmacology

#86

World Rank

#112

Historical Rank

medical Degrees

Download Badge

Medical

Malcolm Rowland's Degrees

PhD Pharmacology University of Manchester
Bachelors Pharmacy University of Nottingham

Why Is Malcolm Rowland Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Malcolm Rowland FBPhS is Emeritus Professor of Pharmacy, University of Manchester, and Adjunct Professor, University of California San Francisco. His research in pharmacology, has been particularly in physiologically based pharmacokinetics . He has written several textbooks on the subject.

(See a Problem?)

Malcolm Rowland's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clinical pharmacokinetics : concepts and applications (1989) (1674)
Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. (2006) (738)
Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. (2005) (631)
Physiologically-based pharmacokinetics in drug development and regulatory science. (2011) (580)
Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. (1973) (518)
Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance (1977) (501)
Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. (1968) (418)
Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine (1995) (356)
Clearance concepts in pharmacokinetics (1973) (350)
Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes (2007) (346)
Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications (1980) (323)
Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response (2011) (298)
Influence of route of administration on drug availability. (1972) (287)
Absorption kinetics of aspirin in man following oral administration of an aqueous solution. (1972) (265)
Lidocaine disposition kinetics in monkey and man; I. Prediction by a perfusion model (1974) (227)
Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs (2006) (223)
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective (2018) (212)
Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. (2001) (210)
DISPOSITION KINETICS OF LIDOCAINE IN NORMAL SUBJECTS * (1971) (202)
Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions (2012) (201)
Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. (1988) (185)
Pharmacokinetics of Acetylsalicylic Acid and Salicylic Acid After Intravenous Administration in Man (1968) (183)
Protein binding in antiretroviral therapies. (2003) (178)
Concept of a volume of distribution and possible errors in evaluation of this parameter. (1968) (168)
Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. (1998) (166)
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. (2011) (163)
Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. (2001) (160)
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. (2011) (160)
A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations (1986) (156)
Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. (1998) (149)
Kinetics of drug-drug interactions (1973) (148)
The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review (2012) (147)
Tissue water content in rats measured by desiccation. (1997) (140)
The Use of Population Pharmacokinetics in Drug Development (1996) (136)
Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. (1999) (136)
Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential (2013) (131)
Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. (2005) (130)
Lumping of Whole-Body Physiologically Based Pharmacokinetic Models (1998) (128)
Enoxacin‐warfarin interaction: Pharmacokinetic and stereochemical aspects (1987) (125)
Lidocaine disposition kinetics in monkey and man; II. Effects of hemorrhage and sympathomimetic drug administration (1974) (125)
Determination of acetylsalicylic acid and salicylic acid in plasma. (1967) (121)
Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125 (1994) (119)
Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans (2000) (119)
Protein Binding and Drug Clearance (1984) (118)
Use of Dried Blood Spots in Drug Development: Pharmacokinetic Considerations (2010) (118)
Physiologic modeling of cyclosporin kinetics in rat and man (1991) (116)
Correlation between in‐vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model (1986) (115)
Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002) (2004) (114)
Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. (1983) (114)
Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liverin situ preparation (1977) (112)
The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man. (1971) (109)
Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. (2010) (109)
Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. (1994) (109)
Pharmacokinetic perspectives on megadoses of ascorbic acid. (1997) (107)
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. (2011) (106)
Interleukin-1 Receptor Antagonist Penetrates Human Brain at Experimentally Therapeutic Concentrations (2008) (105)
Structure-pharmacokinetic relationships among the barbiturates in the rat. (1983) (102)
Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic‐pharmacodynamic model (1994) (101)
Application of salivary salicylate data to biopharmaceutical studies of salicylates. (1972) (100)
Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry (2013) (97)
Introduction to Pharmacokinetics and Pharmacodynamics: The Quantitative Basis of Drug Therapy (2006) (94)
Hepatic elimination--dispersion model. (1985) (92)
Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite (1975) (88)
Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. (1998) (85)
The use of isotopes in the determination of absolute bioavailability of drugs in humans (2006) (84)
Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. (1984) (81)
Absorption kinetics of griseofulvin in man. (1968) (80)
Kinetics of Acetylsalicylic Acid Disposition in Man (1967) (79)
The six-day-old rat air pouch model of inflammation: characterization of the inflammatory response to carrageenan. (1994) (77)
Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics. (1998) (77)
Comparison of HT29-18-C1 and Caco-2 Cell Lines as Models for Studying Intestinal Paracellular Drug Absorption (1996) (76)
Quantitative Structure-Pharmacokinetics Relationships: I. Development of a Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat (1997) (75)
Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda (2007) (74)
Clinical Pharmacokinetics of Teicoplanin (1990) (73)
Influence of acute viral hepatitis on phenytoin kinetics and protein binding (1975) (72)
Cyclosporin-erythromycin interaction in renal transplant patients. (1989) (72)
Physiologic pharmacokinetic models and interanimal species scaling. (1985) (72)
Electrophysiologic Effects of Procaine Amide in Patients with Intraventricular Conduction Delay (1974) (71)
Models of hepatic drug clearance: discrimination between the ‘well stirred’ and ‘parallel‐tube’ models (1983) (71)
Simultaneous liquid-chromatographic quantitation of salicylic acid, salicyluric acid, and gentisic acid in urine. (1980) (71)
An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. (1990) (69)
Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: Lidocaine and indocyanine green (1976) (68)
Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. (2000) (68)
Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide (1977) (66)
Cyclosporin: measurement of fraction unbound in plasma (1987) (64)
A dispersion model of hepatic elimination: 2. Steady-state considerations-influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity (1986) (60)
Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development (2016) (59)
Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. (2008) (59)
Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). (2004) (59)
Stereospecific high-performance liquid chromatographic analysis of warfarin in plasma. (1983) (58)
Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. (2011) (57)
Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans (2004) (56)
Optimal Design for Multivariate Response Pharmacokinetic Models (2006) (55)
Models of hepatic elimination: Comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity, and systemic recycling on hepatic elimination (1988) (53)
Griseofulvin-phenobarbital interaction in man. (1970) (53)
Erythromycin enhances the absorption of cyclosporin. (1988) (53)
Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study (2006) (52)
Cyclosporin-phenytoin interaction: re-evaluation using metabolite data. (1987) (51)
Amphetamine blood and urine levels in man. (1969) (51)
Human clearance prediction: shifting the paradigm (2009) (50)
Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver. (1993) (49)
Influence of albumin on the distribution and elimination kinetics of diclofenac in the isolated perfused rat liver: analysis by the impulse-response technique and the dispersion model. (1993) (49)
Application of salivary concentration data to pharmacokinetic studies with antipyrine. (1977) (49)
Resolution of P‐glycoprotein and non‐P‐glycoprotein effects on drug permeability using intestinal tissues from mdr1a (−/−) mice (2002) (48)
Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. (2001) (48)
Clinical pharmacokinetics and pharmacodynamics (2011) (47)
Microdosing: a critical assessment of human data. (2012) (46)
Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making (2015) (46)
Absorption of prednisolone in patients with Crohn's disease. (1983) (45)
Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin (1976) (45)
Hepatic clearance of drugs. III. Additional experimental evidence supporting the “wellstirred” model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liverin situ preparation (1977) (45)
The warfarin-cimetidine interaction: stereochemical considerations. (1986) (45)
Clinical and electrophysiological effects of intravenous quinidine in man. (1977) (45)
Fuzzy Simulation of Pharmacokinetic Models: Case Study of Whole Body Physiologically Based Model of Diazepam (2004) (44)
Validation of assay methodology used in pharmacokinetic studies. (1987) (42)
Dissociation constants of sparingly soluble substances: nonlogarithmic linear titration curves. (1971) (41)
Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies (2004) (40)
Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine. (1985) (40)
Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. (2001) (38)
Aspirin binding and the effect of albumin on spontaneous and enzyme‐catalysed hydrolysis (1980) (37)
Pharmacokinetics of lidocaine and its deethylated metabolite: Dose and time dependency studies in man (1982) (37)
Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years. (2012) (37)
Influence of Morphometric Factors on Quantitation of Paracellular Permeability of Intestinal Epithelia In Vitro (1997) (37)
The Electrophysiologic Effects of Lidocaine in Patients with Intraventricular Conduction Defects (1974) (36)
A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics (1986) (36)
Empirical versus mechanistic modelling: Comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetic relationships of a homologous series of barbiturates (1999) (36)
Development of a Whole Body Physiologically Based Model to Characterise the Pharmacokinetics of Benzodiazepines. 1: Estimation of Rat Tissue-Plasma Partition Ratios (2004) (35)
Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-ethyl barbituric acid and other compounds. (1995) (35)
Prediction of In Vivo Tissue Distribution from In Vitro Data 1. Experiments with Markers of Aqueous Spaces (2000) (34)
The racemic metoprolol H2‐antagonist interaction (1988) (33)
What surface of the intestinal epithelium is effectively available to permeating drugs? (1998) (33)
A Two‐compartment Dispersion Model Describes the Hepatic Outflow Profile of Diclofenac in the Presence of its Binding Protein (1991) (32)
Influence of fraction unbound upon the renal clearance of furosemide in the isolated perfused rat kidney. (1985) (32)
Phase 0/microdosing approaches: time for mainstream application in drug development? (2020) (31)
Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. (2000) (31)
Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs (2006) (31)
Application of clearance concepts to some literature data on drug metabolism in the isolated perfused liver preparation and in vivo. (1972) (31)
Physiologically Based Pharmacokinetics of Cyclosporine A: Reevaluation of Dose–Nonlinear Kinetics in Rats (1999) (31)
Relationship between renal clearance, protein binding and urine flow for digitoxin, a compound of low clearance in the isolated perfused rat kidney. (1984) (31)
Rodgers T, Rowland M. 2006. Physiologically‐based Pharmacokinetic Modeling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238–1257. (2007) (31)
Introduction to pharmacokinetics and pharmacodynamics (2013) (31)
Route of Administration and Sex Differences in the Pharmacokinetics of Aspirin, Administered as Its Lysine Salt (1989) (31)
Physiologically Based Pharmacokinetic Modeling of a Homologous Series of Barbiturates in the Rat: A Sensitivity Analysis (1997) (30)
Symbols in pharmacokinetics (1980) (30)
Quantitative Structure–Pharmacokinetics Relationships: II. A Mechanistically Based Model to Evaluate the Relationship Between Tissue Distribution Parameters and Compound Lipophilicity (1998) (30)
Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults (1993) (29)
Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. (1990) (28)
Tissue lipids and drug distribution: dog versus rat. (2012) (28)
Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data. (2002) (28)
The influence of gastrointestinal transit on drug absorption in healthy volunteers. (1992) (28)
Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man (2004) (27)
Influence of route of hepatic administration on drug availability. (1984) (27)
In vivo evaluation of Michaelis-Menten constants of hepatic drug-eliminating systems. (1978) (27)
Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice. (1997) (27)
Pharmacokinetics of cyclosporin: influence of rate of constant intravenous infusion in renal transplant patients. (1987) (27)
Simultaneous liquid-chromatographic quantitation of salicylic acid, salicyluric acid, and gentisic acid in plasma. (1979) (26)
Rate and Extent of Absorption of Clonidine from a Transdermal Therapeutic System (1989) (26)
Concentration-time effects of quinidine disposition kinetics in rhesus monkeys. (1977) (26)
Commentary on ACCP Position Statement on the Use of Microdosing in the Drug Development Process (2007) (26)
Two-compartment model for a drug and its metabolite: application to acetylsalicylic acid pharmacokinetics. (1970) (26)
Development of an optimal method for the dual perfusion of the isolated rat liver. (1998) (26)
Commentary: Hepatic Clearance Concepts and Misconceptions: Why the Well-Stirred Model Is Still Used Even Though It Is Not Physiologic Reality? (2019) (26)
Factors influencing non-approval of new drugs in Europe (2012) (26)
A Model to Account for the Variation in Cyclosporin Binding to Plasma Lipids in Transplant Patients (1988) (24)
Protein binding and hepatic clearance: Discrimination between models of hepatic clearance with diazepam, a drug of high intrinsic clearance, in the isolated perfused rat liver preparation (1984) (24)
Application of the axial dispersion model of hepatic drug elimination to the kinetics of diazepam in the isolated perfused rat liver (1992) (24)
Pharmacokinetics : theory and methodology (1986) (24)
A Bayesian Method Based on Clotting Factor Activity for the Prediction of Maintenance Warfarin Dosage Regimens (2003) (23)
Further insight into the stereoselective interaction between warfarin and cimetidine in man. (1991) (23)
Absence of effect of ranitidine on blood alcohol concentrations when taken morning, midday, or evening with or without food (1994) (23)
Relationship between lipophilicity and tubular reabsorption for a series of 5-alkyl-5-ethylbarbituric acids in the isolated perfused rat kidney preparation. (1988) (22)
Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise (2019) (22)
Lead PK commentary: predicting human pharmacokinetics. (2011) (22)
Kinetics of nortiptyline (NT) in rats in vivo and in the isolated perfused liver: demonstration of a 'first pass disappearance' of NT in the liver. (1973) (21)
Estimation of aqueous distributional spaces in the dual perfused rat liver (2000) (21)
Prediction of in Vivo Tissue Distribution from in Vitro Data. 2. Correlation Between in Vitro and in Vivo Tissue Distribution of a Homologous Series of Nine 5-n-Alkyl-5-Ethyl Barbituric Acids (2003) (21)
Kinetics of drug-drug interactions in sheep: tolbutamide and sulfadimethoxine. (1977) (21)
Cyclosporin: Pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration (2004) (21)
Cyclesporin: Erythrocyte Binding and an Examination of Its Use to Estimate Unbound Concentration (1988) (20)
Uncertainty Analysis in Pharmacokinetics and Pharmacodynamics: Application to Naratriptan (2005) (20)
Measurement of Binding of Basic Drugs to Acidic Phospholipids Using Surface Plasmon Resonance and Incorporation of the Data into Mechanistic Tissue Composition Equations to Predict Steady-State Volume of Distribution (2011) (20)
Stereospecific assay of nicoumalone: application to pharmacokinetic studies in man. (1988) (19)
Inter-relationship among individual vitamin K-dependent clotting factors at different levels of anticoagulation. (1987) (19)
Oral Absorption of D-Oligopeptides in Rats via the Paracellular Route (1996) (19)
The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans (1999) (19)
Effects of a non-absorbable osmotic load on drug absorption in healthy volunteers. (1992) (19)
Human Transbuccal Absorption of Diclofenac Sodium from a Prototype Hydrogel Delivery Device (2004) (19)
Effect of route of administration on drug disposition (1973) (19)
New strategies in drug development and clinical evaluation: the population approach (1993) (19)
Protein binding and hepatic clearance: Studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation (1983) (18)
Simultaneous Determination of Tolbutamide and its Metabolites in Biological Fluids (1973) (18)
Getting the Dose Right: Report From the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) Conference on Optimizing Drug Development (2005) (18)
Physiologic Models of Hepatic Drug Elimination (1991) (18)
QUANTITATIVE STRUCTURE PHARMACOKINETIC ACTIVITY RELATIONSHIPS WITH SOME TETRACYCLINES (1979) (18)
A chronic dose-ranging study of the pharmacokinetics of phenylbutazone in rheumatoid arthritic patients. (1981) (18)
Are Physiologically Based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site (2015) (17)
An in vitro study of drug displacement interactions: warfarin‐salicylate and warfarin‐phenylbutazone (1979) (17)
Impact of target interactions on small-molecule drug disposition: an overlooked area (2018) (17)
Commentary on “The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio” (2018) (16)
Physiologic models of hepatic drug clearance: influence of altered protein binding on the elimination of diclofenac in the isolated perfused rat liver. (1993) (16)
Use of carbon disulfide as a solvent for the silylation of submicrogram amounts of carboxylic acids. (1967) (16)
Population approaches in drug development (1994) (16)
Pharmacometrics: A new journal section (1982) (15)
Estimation of reference space in the perfused rat hindlimb (1994) (15)
Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. (1983) (15)
Warfarin metabolites: stereochemical aspects of protein binding and displacement by phenylbutazone. (1993) (15)
Pharmacokinetics of individual components of teicoplanin in man (1990) (15)
Toward an integrated human clearance prediction strategy that minimizes animal use. (2011) (15)
Liquid chromatographic determination of lipophilicity with application to a homologous series of barbiturates. (1984) (15)
A study to assess the anticholinergic activity of rolipram in healthy elderly volunteers. (1988) (15)
Importance of target-mediated drug disposition for small molecules. (2018) (14)
Saturable Binding of Cyclosporin A to Erythrocytes: Estimation of Binding Parameters in Renal Transplant Patients and Implications for Bioavailability Assessment (1988) (14)
The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose, Commission of the European Community, Luxembourg (1997) (14)
Prediction of in Vivo Tissue Distribution from in Vitro Data. 2. Influence of Albumin Diffusion from Tissue Pieces During an in Vitro Incubation on Estimated Tissue-to-Unbound Plasma Partition Coefficients (Kpu) (2003) (14)
Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products. (2018) (14)
Further considerations of the "single-point single-dose" method to estimate individual maintenance dosage requirements. (1982) (13)
Determination of phenylbutazone, tolbutamide and metabolites in plasma and urine using chemical ionization mass spectrometry. (1977) (13)
Absorption kinetics of cyclosporin in the rat (1992) (13)
Simple method for the optimisation of mobile phase composition for high-performance liquid chromatographic analysis of a multi-component mixture (1981) (13)
Absorption of polar drugs following caecal instillation in healthy volunteers (1992) (13)
Distribution Kinetics of Salicylic Acid in the Isolated Perfused Rat Liver Assessed Using Moment Analysis and the Two-Compartment Axial Dispersion Model (1994) (13)
Modulation of the Permeability of H 2 Receptor Antagonists Cimetidine and Ranitidine by P-Glycoprotein in Rat Intestine and the Human Colonic Cell Line Caco-21 (1998) (13)
Absorption of clonidine from a transdermal therapeutic system when applied to different body sites (1984) (12)
Regional Drug Delivery II: Relationship Between Drug Targeting Index and Pharmacokinetic Parameters for Three Non-Steroidal Anti-Inflammatory Drugs Using the Rat Air Pouch Model of Inflammation (1995) (11)
Pharmacokinetics of prednisone and prednisolone at steady state in the rabbit. (1985) (11)
Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs. (1987) (11)
In vitro studies of teicoplanin binding to rat tissues and erythrocytes. (1998) (10)
A Physiologically Based Pharmacokinetic Model Incorporating Dispersion Principles to Describe Solute Distribution in the Perfused Rat Hindlimb Preparation (1997) (10)
Distribution kinetics of salicylic acid in the dual-perfused rat liver preparation. (1999) (10)
Pharmacokinetics of imipenem and cilastatin after their simultaneous administration to the elderly. (1987) (9)
Representation and interpretation of drug displacement interactions. (1978) (9)
Effect of altered tissue binding on the disposition of barbital in the isolated perfused rat liver: application of the axial dispersion model. (1997) (9)
A simple restraining device for chronic pharmacokinetic and metabolism studies in rats. (1981) (9)
Pharmacokinetic considerations of regional administration and drug targeting: Influence of site of input in target tissue and flux of binding protein (1996) (9)
Protein binding and hepatic extraction of diazepam across the rat liver (1983) (9)
Pitfalls in assessing the radiopurity of tritiated steroids by high-performance liquid chromatography (1983) (9)
Absorption kinetics of a series of local anesthetics from rat subcutaneous tissue. I (1974) (9)
Correction for Nonspecific Binding to Various Components of Ultrafiltration Apparatus and Impact on Estimating In Vivo Rat Clearance for a Congeneric Series of 5-Ethyl, 5-n-Alkyl Barbituric Acids (2011) (8)
Kinetics of drug displacement interactions (1981) (8)
Estimation of specific hepatic arterial water space. (1998) (8)
Rodgers T, Leahy D, Rowland M. 2005. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate‐to‐strong bases. J Pharm Sci 94:1259–1276. (2007) (8)
Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state (2005) (8)
Distribution of antipyrine in the rat liver (1992) (8)
Pharmacodynamic Comparison of Regional Drug Delivery for Non‐steroidal Anti‐inflammatory Drugs, Using the Rat Air‐pouch Model of Inflammation (1995) (8)
Cimetidine-nicoumalone interaction in man: stereochemical considerations. (1989) (7)
Intra‐Target Microdosing (ITM): A Novel Drug Development Approach Aimed at Enabling Safer and Earlier Translation of Biological Insights Into Human Testing (2017) (7)
Experimental determination of a drug targeting index for S(+)ibuprofen using the rat air pouch model of inflammation. (1994) (7)
Regional Drug Delivery I: Permeability Characteristics of the Rat 6-Day-Old Air Pouch Model of Inflammation (1995) (7)
Determination of 6-demethylgriseofulvin in urine. (1973) (7)
Intra‐Target Microdosing – A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans (2017) (6)
Free communicationFC52 distribution of 5-alkyl-5-ethyl barbituric acids in the perfused rat hindlimb (1994) (6)
Determination of Aqueous Solubilities of a Series of 5-Ethyl-5-Alkylbarbituric Acids and Their Correlation with Log P and Melting Points (1984) (6)
Binding of Sulfonamides to Carbonic Anhydrase: Influence on Distribution Within Blood and on Pharmacokinetics (1989) (6)
Addendum 1. Use of isotopes in bioavailability testing (1973) (6)
Discrepancies in pharmacokinetic parameter estimation between bolus and infusion studies in the perfused rat hindlimb (1995) (6)
The clinical pharmacology of salicylates. (1969) (6)
Interview: Interview with Professor Malcolm Rowland. (2010) (6)
Influence of erythrocytes on the hepatic distribution kinetics of urea and thiourea. (2007) (5)
Pharmacokinetics of cyclosporin: influence of rate-duration profile of an intravenous infusion in renal transplant patients. (1989) (5)
Use of in vitro dissolution data to predict plasma drug profiles. (1977) (5)
Bioavailability assessment and pharmacologie response: Impact of first-pass loss when both drug and metabolites are active (1988) (5)
Evaluation of route of input on the hepatic disposition of diazepam. (2000) (5)
Functional modelling of tight junctions in intestinal cell monolayers using polyethylene glycol (PEG) oligomers. (2001) (5)
Development of an assay for the extraction and quantification of nine 5-n-alkyl-5-ethyl barbituric acids in various rat tissues. (1999) (5)
Development of a system for studying subcutaneous absorption kinetics of local anesthetic amines. (1972) (5)
In Defense of Current Concepts and Applications of Clearance in Drug Development and Therapeutics (2021) (5)
A simple system for the investigation of protein binding effects on the renal handling of drugs in an isolated perfused rat kidney preparation. (1984) (5)
The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. (2005) (5)
Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to children. (1998) (5)
A chronic dose-ranging kinetic study of salicylate in man [proceedings]. (1977) (5)
Renal handling of warfarin metabolites in man (1994) (5)
INTRODUCING PHARMACOKINETIC AND PHARMACODYNAMIC CONCEPTS* (2001) (4)
Model choice for teicoplanin kinetics in man. (1991) (4)
A comparison of the relative sensitivities of factor VII and prothrombin time measurements in detecting drug interactions with warfarin (2004) (4)
Microdosing of protein drugs (2016) (4)
A whole body physiologically-based pharmacokinetic model incorporating dispersion principles (2001) (4)
A Comment on the “Correction” of Tissue–Plasma Partition Coefficients for Drug Extraction in Eliminating Organs by Sven Björkman (2005) (3)
CLINICAL TRIALS AND TRANSLATIONAL MEDICINE COMMENTARIES Microdosing: A Critical Assessment of Human Data (2012) (3)
Effect of erythrocytes on the hepatic distribution kinetics of antipyrine (2010) (3)
1453 – POSTURE AND LIGNOCAINE PHARMACOKINETICS IN HUMAN VOLUNTEERS (1978) (3)
Molecular expression of polyspecific drug transporters in human intestine (1999) (3)
Optimal Experimental Design for Precise Estimation of the Parameters of the Axial Dispersion Model of Hepatic Elimination (1998) (3)
Representation and quantitation of the binding interaction between prednisone, prednisolone and corticosteroid binding globulin (1984) (3)
Dedication to Professor Leslie Z. Benet: 50 Years of Scientific Excellence and Still Going Strong! (2012) (3)
Acceptable sampling times at plateau for drug analysis. (1981) (3)
Comprehensive Pharmacokinetics of Urinary Human Follicle Stimulating Hormone in Healthy Female Volunteers (1995) (3)
Application of the Dispersion Model to Describe Disposition Kinetics of Markers in the Dual Perfused Rat Liver (2007) (3)
Effects of H2-receptor antagonists on blood alcohol levels. (1992) (3)
P161 development of a whole-body physiologically based pharmacokinetic model using dispersion concepts (1994) (2)
Empirical versus mechanistic modeling: Comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetics relationship (1999) (2)
IS THE PERIPHERAL SINK HYPOTHESIS PHYSIOLOGICALLY FEASIBLE? EVIDENCE FROM MODEL-BASED ASSESSMENT OF THE AMYLOID PATHWAY (2016) (2)
Hemodynamic factors in pharmacokinetics. (1975) (2)
RELATIVE PARTITION COEFFICIENT MEASUREMENTS BY HPLC (1980) (2)
Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential (2012) (2)
Use of a single-pass in situ perfused rat hindlimb to study tissue distribution kinetics. Method development and experiences with Evans blue. (2000) (2)
Critique of cyclosporine pharmacokinetic measurements. (1986) (2)
Interpretation of microsampling data during drug development and regulatory considerations (2013) (2)
INFLUENCE OF LIPOPHILICITY ON THE RENAL CLEARANCE OF A SERIES OF 5‐ETHYL‐5‐ALKYLBARBITURIC ACIDS IN THE ISOLATED PERFUSED RAT KIDNEY PREPARATION (1982) (2)
Transport of acyclovir across cell membranes: Studies with rat erythrocyte and perfused liver (1996) (1)
Proceedings: Pharmacokinetics: a basis for rational design, development and clinical application of drugs. (1974) (1)
Synthesis and characterisation of D-amino acid-based oligopeptides for use as probes of the influence of molecular structure on the paracellular route of gastrointestinal drug uptake (1997) (1)
Influence of site on the intestinal absorption of D-peptides: Findings in the in situ perfused rat intestine. (1996) (1)
Pharmacokinetics ofcyclosporin: influence ofrate ofconstant intravenous infusion inrenal transplant patients (1987) (1)
Use of the isolated wild type and mdr1a (-/-) mouse intestine in the study of drug transport mechanisms in vitro (2001) (1)
Absorption and Excretion of Clonidine Following Application of Catapres-TTS to Different Skin Sites (1985) (1)
A whole body physiologically based pharmacokinetic model for the distribution of barbiturates in rats (1996) (1)
Whole body physiologically based modelling of β‐blockers in the rat: events in tissues and plasma following an i.v. bolus dose (2018) (1)
Clearance — Models, Validation and Implications (1984) (1)
Hepatic clearance models and IVIVE predictions (2022) (1)
Disposition kinetics of diclofenac in the dual perfused rat liver. (2013) (1)
PHARMACOKINETICS OF SALICYLATE AFTER CHRONIC DOSING IN MAN (1978) (1)
Functional proflling of intestinal tight junctions in vitro highlights mechanistic differences between tight junction modulators (2001) (1)
Computer lung modelling to predict inhaled particle deposition: a comparison of predicted and clinical data (1999) (1)
Erratum to: Quantitative Structure-Pharmacokinetics Relationships: I. Development of Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat (1998) (1)
Incorporating Variability and Uncertainty into the In Vitro - In Vivo Predictioon of Hepatic Clearance. Proc. 5th EUFEPS Conference: Optimising Drug Development: Fastracking into Human, Wiesbaden, Germany, December 1998 (1998) (1)
Dedication to Professor Leslie Z. Benet: 50 Years of Scientific Excellence and Still Going Strong! (2012) (0)
Effects ofLidocaine in Patients withIntraventricular Conduction Defects (1974) (0)
Construction of a stereochemical and physiologically based model of three beta adrenergic blocking agents (1999) (0)
EIGHTH ANNUAL PHARMACOKINETICS COURSE FOR PHARMACEUTICAL SCIENTISTS ONE-WEEK WORKSHOP ON ADVANCED METHODS IN PHARMACOKINETICS (2004) (0)
Influence of protein binding on hepatic distribution kinetics of antisense oligonucleotides. (1998) (0)
Estimation of specific hepatic arterial water space. (1998) (0)
A mechanistically based model for the relationship between the tissue distribution parameters and the lipophilicity of a homologous series of barbiturates in rats (1999) (0)
Evaluation of route of input on hepatic disposition of diazepam in the dual perfused rat liver (1996) (0)
Contributors (2022) (0)
Development of an assay for the extraction and quantification of nine 5-ethyl-5-alkyl barbituric acids in various rat tissues. (1999) (0)
Preparation, characterization, and anti-tumor effects of A5B7-CMdextran-cisplatin conjugates (1994) (0)
Multiple efflux processes influence intestinal drug absorption: studies using tissues from the mdr1a(-/-) mouse (2001) (0)
A Physiologically Based Pharmacokinetic Model Incorporating Dispersion Principles to Describe Solute Distribution In the Perfused (1997) (0)
Investigations into thepotential effects ofmultiple doseketorolac on thepharmacokinetics andpharmacodynamics ofracemic (1990) (0)
Incorporating measures of physiological variability into physiologically based pharmacokinetic modeling (2000) (0)
Program (ACoP7) (2016) (0)
Phase 0/microdosing approaches: time for mainstream application in drug development? (2020) (0)
Analysis of transporter expression in vinblastine-selected Caco-2 cells (2000) (0)
Placebo controlled double‐blind randomised cross‐over trial of atenolol, hydrochlorthiazide and amiloride, and the combination (Kalten) in patients over 60 years of age (1986) (0)
British Pharmaceutical Conference 1993. Science proceedings, 130th meeting. Chiltern, September 21-24, 1993. Abstracts. (1993) (0)
Comparison of Serum Bilirubin Levels in Humans and Two Monogastric Animal Species After a Single Administration of Sulfisoxazole (1982) (0)
Molecular expression of multiple claudin isoforms in the human intestine (2001) (0)
Regional Variation in intestinal permeability; morphological and experimental conditions (1997) (0)
Towards prediction of oral bioavailability from in situ permeability data, using PEG 400 as a probe (1997) (0)
Introductory statement (2005) (0)
Choice of the boundary conditions for the axial dispersion model in the analysis of hepatic outflow data (2000) (0)
P160 distribution kinetics of salicylic acid in isolated perfused cirrhotic rat liver (1994) (0)
Editorial to the Third Issue Dedicated to Lewis Sheiner (2006) (0)
Influence of morphometric variation on paracellular permeability characteristics of intestinal epithelia in vitro. (1997) (0)
CLINICAL AND ELECTROPHYSIOLOGICAL EFFECTS OF INTRAVENOUS QUINIDINE IN MAN (1978) (0)
Inhibitors of myosoin light-chain kinase modulate tight junctions in Caco-2 cells (1996) (0)
Pethidine pharmacokinetics in dog" dose and time studies [proceedings]. (1976) (0)
ON REPRESENTATION AND INTERPRETATION OF DRUG DISPLACEMENT INTERACTIONS (1977) (0)
Effect of perfusate protein on the hepatic distribution of a phosphorothioate antisense oligonucleotide. (1997) (0)
Prediction and evaluation of pharmaco-kinetics in drug discovery and lead optimisation (2005) (0)
Physiologically-based pharmacokinetics (PBPK) : model development and application (2005) (0)
When drug therapy causes diarrhea. (1989) (0)
Kinetic analysis of digoxin efflux in rat and human intestinal epithelia in vitro (2000) (0)
Incorporating variability and uncertainty into interspecies scaling of pharmacokinetics. In IFAC "Modelling and Control in Biomedical systems".(Edited by E.Carlson & E. Ssalzsieder) (2000) (0)
Physiologically based pharmacokinetc modeling of a homologous series of barbiturates in the rat. II. A Sensitivity analysis of the model. (1997) (0)
Pharmacokinetics ofcyclosporin: influence ofrate-duration profile ofanintravenous infusion inrenal transplant patients (1989) (0)
PHYSIOLOGICAL PHARMACOKINETICS: ITS PLACE IN DRUG DEVELOPMENT AND USE (1992) (0)
Erratum to: Bioavailability assessment and pharmacologie response: Impact of first-pass loss when both drug and metabolites are active (2005) (0)
Meeting announcement (2005) (0)
New safe medicines faster. (2001) (0)
Prediction of hepatic clearance of benzodiazepines in rats: comparison of isolated hepatocytes and microsomes. (1999) (0)
Cross validation of in situ and in vitro models of intestinal paracellular absorption using PEG 400 (1997) (0)
INTERACTION BETWEEN PREDNISOLONE AND PREDNISONE FOR BINDING SITES ON PLASMA PROTEINS (1982) (0)
Fuzzy simulations of pharmacokinetic models: a study with naratriptan (2001) (0)
Differential expression of ABC transporters in vinblastine-selected intestinal Caco-2 cells (2000) (0)
Relationship between lipophilicity and protein binding of a homologous series of barbiturates (2002) (0)
Estimation of hepatic arterial water space (1998) (0)
On representation and interpretation of drug displacement interactions [proceedings]. (1977) (0)
P158 effect of temperature on the distribution of barbiturate in isolated perfused rat liver (1994) (0)
Future perspectives of microsampling in pharmaceutical development (2013) (0)
Potential errors associated with the in vivo estimation of tissue to plasma partition coefficients (1996) (0)
Poster Session 2 — Pharmacokinetics (2002) (0)
Investigation of specific hepatic arterial water space in the dual perfused rat liver (1999) (0)
Editorial to the First Issue Dedicated to Lewis Sheiner (2005) (0)
CYCLICINTERCONVERSIONOFVITAMINK1AND VITAMIN K12,3-EPOXIDE INMAN (1983) (0)
Differential sensitivity of drug efflux to inhibitors of p-glycoprotein and MRP transporters in Caco-2 cells and isolated, stripped rat ileal mucosa. (2000) (0)
Transepithelial permeability of ranitidine across rat ileum and Caco-2 monolayers is modified by P-glycoprotein (1997) (0)
Editorial to the Second Issue Dedicated to Lewis Sheiner (2006) (0)
Correlation between in Vitro and in Vivo Tissue Distribution of a Homologous Series of Nine 5n-Alkyl-5-Ethyl Barbituric Acids (0)
Prediction of oral bioavailability from in situ perfusion data: Investigation of tight functional density and pore size in the rat jejunum and ileum (1999) (0)
Species differences in size discrimination in oral bioavailability reflected by polyethylene glycols markers of intestinal paracellular permeability (1997) (0)
Meeting announcements (2005) (0)
Oral bioavailability of paracellularly absorbed D-oligopeptides: rat versus dog (1997) (0)
P159 estimation of vascular, extravascular and intracellular distribution spaces in the dual perfused rat liver (1994) (0)
Critical issues in tumor microcirculation, angiogenesis and metastasis: Biological significance and clinical relevance (2004) (0)
Influence of rat intestine p-glycoprotein on the permeability of hydrophillic and lipophilic drugs in vitro (1997) (0)
Current developments in pharmacokinetics (1985) (0)
In vitro - in vivo hepatic clearance prediction using fuzzy sets (2000) (0)
Molecular expression of p-gp, MRP and C-MOAT in the human gastrointestinal tract. (2000) (0)
British Pharmaceutical Conference 1993 : variability and the individual reading, September 21-24, 1993 (1994) (0)
Are Physiologically Based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site (2015) (0)
Scheele lecture. Pharmacokinetics: concepts, insights and applications. (1986) (0)
924 – SALICYLATE BINDING AND THE EFFECT OF BINDING ON THE RATE OF ASPIRIN HYDROLYSIS IN VITRO (1978) (0)
The hepatocellular binding of a phosphorothioate (P=S) antisense oligonucleotide, ISIS 1082. (1998) (0)
A physiologically-based pharmacokinetic model for the distribution of barbiturates in rats. AAPS Tenth Anniversary Meeting, 27-31 October 1996, Seattle, Washington (1996) (0)
Preclinical prediction of human pharmacokinetics (2022) (0)

This paper list is powered by the following services:

Other Resources About Malcolm Rowland

en.wikipedia.org

What Schools Are Affiliated With Malcolm Rowland?

Malcolm Rowland is affiliated with the following schools:

Malcolm Rowland's Academic­Influence.com Rankings